Search research articles
Contact Us
Filters
Showing results (61-70 of 106) with videos related to
Page
of 11
Sort By:
Blood Advances
|
January 11, 2023
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
Hye Kyung Lee, Manuela A Hoechstetter, Maike Buchner, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 29, 2022
Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination
Hye Kyung Lee, Manuela A Hoechstetter, Maike Buchner, et al.
The Journal of Experimental Medicine
|
September 17, 2014
Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction
Peter D Kurktschiev, Bijan Raziorrouh, Winfried Schraut, et al.
Leukemia & Lymphoma
|
May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
Paula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Blood Advances
|
August 16, 2022
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study
Thomas Wimmer, Raphael Mattes, Hans-Joachim Stemmler, et al.
Blood
|
June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Paula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Leukemia & Lymphoma
|
August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Haematologica
|
August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)
Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology
|
June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 106) with videos related to
Sort By:
Page
of 11
Blood Advances
|
January 11, 2023
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
Hye Kyung Lee, Manuela A Hoechstetter, Maike Buchner, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 29, 2022
Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination
Hye Kyung Lee, Manuela A Hoechstetter, Maike Buchner, et al.
The Journal of Experimental Medicine
|
September 17, 2014
Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction
Peter D Kurktschiev, Bijan Raziorrouh, Winfried Schraut, et al.
Leukemia & Lymphoma
|
May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
Paula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Blood Advances
|
August 16, 2022
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study
Thomas Wimmer, Raphael Mattes, Hans-Joachim Stemmler, et al.
Blood
|
June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Paula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Leukemia & Lymphoma
|
August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor
Philipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Haematologica
|
August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)
Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology
|
June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Page
of 11